Case Study: CareMetx Omnichannel Program Drives Initiation and Persistence for a Self-Injectable Rheumatology Biologic

Self-injectable drugs help patients manage chronic conditions from the convenience of home, yet they’re more complicated to administer than oral drugs, creating barriers for patients to initiate and stay on therapy. Patients with a chronic inflammatory disease can encounter obstacles throughout the care journey—from poor health and low literacy before the diagnosis, to anxiety about the injection process once they receive a RX, to lack of motivation and side effects concerns throughout their therapy.

CareMetx Omnichannel Program Drives Initiation FI

 

Download the case study PDF to read more

Download Now

 

Case Study: CareMetx Saves $12 Million for Leading Office-Based Injectable

This manufacturer of a leading office-based injectable sought an automated, cost-effective way to tackle those administrative burdens to help ensure...

Read More

Case Study: CareMetx Transforms Medical Benefit Verification and Prior Authorization Processes for Pharmaceutical Manufacturer

When a provider prescribes a patient a specialty therapy, the next steps often involve a complex navigation of cumbersome, multi-step authorization...

Read More

Case Study: Fully Integrated CareMetx Program Improves Initiation and Days on Therapy

A leading pharmaceutical manufacturer partnered with CareMetx to improve initiation rates and time on therapy for a self-injected...

Read More